What genetic variants are associated with Hypertension (Essential)?

Key pharmacogenomic variants: rs699 in AGT, rs5186 in AGTR1. Genes involved: AGT, AGTR1, ACE, ADD1, CYP11B2.

How can PepFold help with Hypertension (Essential) research?

PepFold accepts the rsIDs associated with Hypertension (Essential) (rs699, rs5186) and generates computational peptide candidates targeting the affected proteins. Each candidate comes with predicted 3D structures, 10-dimension scoring, and Fmoc-SPPS synthesis protocols.

Condition Database

Hypertension (Essential)

Prevalence: 1.3 billion adults worldwide (~30% of adult population)

Essential hypertension affects 1.3 billion adults worldwide. AGT (rs699) and AGTR1 (rs5186) variants modulate the renin-angiotensin-aldosterone system (RAAS), the primary pharmacological target for blood pressure control.

Peptide Therapeutics

Angiotensin receptor-blocking peptides, renin inhibitor peptides, natriuretic peptide analogs (ANP, BNP, CNP), and ACE2-derived peptides are established and emerging therapeutic approaches.

Current Treatments

ACE inhibitors, ARBs, calcium channel blockers, thiazide diuretics, beta-blockers. Nesiritide (natriuretic peptide) for acute heart failure.

Key Genetic Variants

rs699~42% global (Thr allele)

AGT — Met235Thr

rs5186~30% global (C allele)

AGTR1 — A1166C

Explore peptide candidates for Hypertension (Essential)

Submit rs699, rs5186 to PepFold. Full report with 3D structures and synthesis protocols in under 2 minutes.

Try Analysis View Pricing